Federated Hermes
NGM

Federated Hermes’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Federated Hermes’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-345,381
Closed -$297K – 2170
2023
Q4 		$297K Sell
345,381
-240,208
-41% -$211K ﹤0.01% 1453
2023
Q3 		$627K Buy
585,589
+104
+0% +$215 ﹤0.01% 1271
2023
Q2 		$1.52M Buy
585,485
+412,097
+238% +$1.47M ﹤0.01% 1043
2023
Q1 		$707K Buy
+173,388
New +$801K ﹤0.01% 1292
2022
Q1 		– Sell
-1
Closed -$1K – 2358
2021
Q4 		$1K Sell
1
-6,627
-100% -$127K ﹤0.01% 2173
2021
Q3 		$139K Sell
6,628
-50
-0.7% -$1.1K ﹤0.01% 1728
2021
Q2 		$132K Buy
+6,678
New +$156K ﹤0.01% 1747
2020
Q4 		– Sell
-2,425
Closed -$39K – 2364
2020
Q3 		$39K Sell
2,425
-256
-10% -$4.67K ﹤0.01% 1817
2020
Q2 		$53K Sell
2,681
-625
-19% -$11.9K ﹤0.01% 1774
2020
Q1 		$41K Sell
3,306
-481
-13% -$7.85K ﹤0.01% 1719
2019
Q4 		$70K Buy
+3,787
New +$55.4K ﹤0.01% 1711

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes's NGM Position: Q1 2024 in Review

Federated Hermes sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 345,381 shares — an estimated $297K sold.

Federated Hermes first reported a position in NGM in Q4 2019 and held it in 11 quarters. The position peaked at $1.52M in Q2 2023. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Federated Hermes reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Federated Hermes sold 345,381 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $297K.
  • Federated Hermes first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Federated Hermes's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.52M in Q2 2023.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Federated Hermes's 13F filing for Q1 2024, filed 14 May 2024.